Royalty Pharma RPRX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total income and other revenues by Product | |||||
| Income from financial royalty assets | $2.26B+5.2% | $2.15B-2.2% | $2.2B+3.4% | $2.13B+2.9% | |
| Other royalty income and revenues | $117.04M+2.5% | $114.15M-27.2% | $156.8M+39.9% | $112.12M+111% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Royalty Pharma break its business down?
- Royalty Pharma (RPRX) reports total income and other revenues by product across 2 parts — Income from financial royalty assets and Other royalty income and revenues. Each is extracted from the segment footnotes and tracked over time.
- Where does Royalty Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Royalty Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
